Panel: What is new on the vaccine policy and country support front?

Aurélia Nguyen

Chief Programme Officer, Gavi, the Vaccine Alliance

ARVAC, 12 June 2024

How Gavi achieves impact: creating value for all

Long-term funding

Pooling demand of lowest-income countries

Accelerating access to vaccines

Shaping markets for affordable vaccine products

Strengthening vaccine delivery platforms

Sustaining immunisation and transition


Market shaping

Donor base

Co-financing














>1 billion immunised; >68 million in 2022 alone






ccines supported against # of infectious diseases


Gavi's vaccine portfolio has significantly grown over time





¹ Diphtheria, tetanus, pertussis (DTP) boosters, hepatitis B, Haemophilus influenzae type b (Hib), 3 PEP = Postexposure prophylaxis


Closing the immunisation gap: a long road ahead



*Sources: WHO/UNICEF Estimates of National Immunization Coverage, July 2023; United Nations Population Division World Population Prospects, 2022




How Gavi supports countries: three key financing levers



^{*2021-2025} forecast expenditure excluding COVAX support

Making immunisation sustainable: Gavi support evolves with country income, co-financing capacity




Eligibility and transition model at risk: backsliding, fiscal challenges



Countries use Gavi's support to invest in health system areas critical for immunisation

% of Health Systems Strengthening and Equity Accelerator Fund allocations by programmatic area Grants approved in Gavi 5.0/5.1



Gavi 6.0: centred around the Alliance's core mandate and addressing key contextual trends



